Truist Financial Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Dianthus Therapeutics (NASDAQ:DNTH) had its target price lifted by Truist Financial from $63.00 to $110.00 in a research report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts also recently issued research reports about the company. Wedbush raised their price objective on Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Jefferies Financial Group increased their target price on shares of Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. HC Wainwright raised their target price on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $98.67.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $79.23 on Monday. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $84.86. The business has a fifty day moving average price of $49.17 and a 200-day moving average price of $41.17. The firm has a market capitalization of $3.42 billion, a price-to-earnings ratio of -22.77 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, equities research analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently made changes to their positions in DNTH. Caitong International Asset Management Co. Ltd purchased a new position in Dianthus Therapeutics in the fourth quarter worth about $43,000. Seven Fleet Capital Management LP purchased a new stake in Dianthus Therapeutics during the fourth quarter valued at approximately $604,000. Invesco Ltd. lifted its stake in shares of Dianthus Therapeutics by 125.9% in the 4th quarter. Invesco Ltd. now owns 101,489 shares of the company’s stock valued at $4,182,000 after purchasing an additional 56,560 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at approximately $550,000. Finally, Voloridge Investment Management LLC boosted its holdings in shares of Dianthus Therapeutics by 80.5% in the 4th quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company’s stock worth $1,627,000 after purchasing an additional 17,612 shares during the period. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics News Summary

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision in the Phase 3 CAPTIVATE CIDP trial — interim responder analysis met the company’s GO criteria (20 confirmed responders with fewer than 40 Part A completers); company will keep the 300mg S.C. Q2W dose and plans regulator engagement, a material clinical de‑risking event and the primary catalyst for the rally. Dianthus Announces Early GO Decision
• Positive Sentiment: Analyst upgrades/price‑target increases — HC Wainwright raised its target to $130 (buy) and Truist raised its target to $110 (buy). Upgrades increase buy‑side visibility and can amplify momentum after positive trial news. Benzinga
• Neutral Sentiment: Conference call/webcast to discuss interim responder analysis — management hosted a call to provide details, giving investors more color on the result and regulator engagement plans (increases transparency but depends on call tone). Dianthus to Host Conference Call
• Neutral Sentiment: Press and valuation pieces are drawing attention — several articles are re‑evaluating DNTH’s valuation after strong share gains, which can attract momentum traders and long‑term reallocations. Investors.com Yahoo Finance
• Neutral Sentiment: Short‑interest data shows 0 shares (report appears to be an artifact) — this reported figure is not meaningful and should not be interpreted as bearish evidence.
• Negative Sentiment: Filed a proposed $400M underwritten public offering (plus up to $60M option) — large equity raises typically dilute existing holders; while proceeds can fund development and commercialization, the market often treats such filings as near‑term negative. Dianthus Announces Proposed $400M Offering
• Negative Sentiment: Q4 earnings miss — reported loss of $1.43/share vs. consensus of ~$0.98 and negative margins/ROE; weaker results can temper enthusiasm and help explain the need for a capital raise. Zacks: Q4 Loss, Miss

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.